Keyword: Pfizer

Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.

Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.

Neurodegenerative disease startup QurAlis has extended the seed round it first announced in April, bringing its total funding up to $5.5 million.

Pfizer is joining forces with Novartis to treat NASH and try to get a slice of a potentially multibillion-dollar future market.

Pfizer and Eli Lilly have inched closer to getting their NGF blocker tanezumab to the filing stage as an alternative to opioids for chronic pain.

The data could tee Bayer up to compete with Johnson & Johnson and Pfizer for a previously underserved population of prostate cancer patients.

Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.

Intellia Therapeutics is developing a CRISPR-based treatment to edit the mutation that causes transthyretin amyloidosis.

Merck beefs up digital work with consumer executive; F-star names ex-Immunocore CEO as leader; and Ziopharm’s R&D head joins Spectrum as CMO.

DFCI's Haining to become VP, Oncology at Merck; Pfizer poaches Quest exec to spearhead digital; and Perrigo swaps CEO for former tobacco executive.